Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]).
Immunotherapy with Interleukin-2 (IL-2) and LAK cells has shown antitumoral activity in metastatic cancer patients. So far, thrombocytopenia is the major side effect reported in hemostasis. We have studied coagulation parameters in 6 patients treated with r-Met Hu IL-2 [ala-125]. In each case, we have observed a significant fall in prothrombin time, fibrinogen, protein C, anti-thrombin III, plasminogen, alpha 2-antiplasmin and all of the clotting factors except factor VIII. There was a significant increase in the activated thromboplastin time. No significant modifications of the D-Dimer test, fibrin-fibrinogen degradation products (FDP) and thrombin time were observed. Our data suggest that r-Met Hu IL-2 [ala-125] could interfere with the hepatic synthesis of the clotting factors and their inhibitors.
Richard
V
V
Service de Médecine et Laboratoire d'Investigation Clinique H. J. Tagnon, Institut Jules Bordet, l'Université Libre de Bruxelles, Belgium.
Bernier
M
M
Themelin
L
L
Bron
D
D
Sculier
J P
JP
D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects*; D009369:Neoplasms / Q000097:blood* / Q000628:therapy; D010314:Partial Thromboplastin Time; D010865:Pilot Projects; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000009:adverse effects*
D001779:Blood Coagulation Factors; D007376:Interleukin-2; D011994:Recombinant Proteins; D005340:Fibrinogen